vs
MACERICH CO（MAC）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
MACERICH CO的季度营收约是Orthofix Medical Inc.的1.2倍（$261.7M vs $219.9M），Orthofix Medical Inc.净利率更高（-1.0% vs -7.2%，领先6.2%），Orthofix Medical Inc.同比增速更快（2.0% vs -4.4%），过去两年MACERICH CO的营收复合增速更高（12.0% vs 8.0%）
Macerich是一家专注于购物中心投资的房地产投资信托基金，为美国第三大购物中心持有及运营商。截至2024年12月31日，公司共持有43处物业的权益，可租赁总面积达4300万平方英尺，公司名称由创始人Mace Siegel与Richard Cohen的名字组合而来。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
MAC vs OFIX — 直观对比
营收规模更大
MAC
是对方的1.2倍
$219.9M
营收增速更快
OFIX
高出6.3%
-4.4%
净利率更高
OFIX
高出6.2%
-7.2%
两年增速更快
MAC
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $261.7M | $219.9M |
| 净利润 | $-18.8M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | — | 0.2% |
| 净利率 | -7.2% | -1.0% |
| 营收同比 | -4.4% | 2.0% |
| 净利润同比 | 91.1% | 92.4% |
| 每股收益（稀释后） | $-0.08 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MACOFIX
| Q4 25 | $261.7M | $219.9M | ||
| Q3 25 | $253.3M | $205.6M | ||
| Q2 25 | $249.8M | $203.1M | ||
| Q1 25 | $249.2M | $193.6M | ||
| Q4 24 | $273.7M | $215.7M | ||
| Q3 24 | $220.2M | $196.6M | ||
| Q2 24 | $215.5M | $198.6M | ||
| Q1 24 | $208.8M | $188.6M |
净利润MACOFIX
| Q4 25 | $-18.8M | $-2.2M | ||
| Q3 25 | $-87.4M | $-22.8M | ||
| Q2 25 | $-40.9M | $-14.1M | ||
| Q1 25 | $-50.1M | $-53.1M | ||
| Q4 24 | $-211.2M | $-29.1M | ||
| Q3 24 | $-108.2M | $-27.4M | ||
| Q2 24 | $252.0M | $-33.4M | ||
| Q1 24 | $-126.7M | $-36.0M |
毛利率MACOFIX
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% | ||
| Q1 24 | — | 67.5% |
营业利润率MACOFIX
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | -8.3% | ||
| Q2 25 | — | -7.9% | ||
| Q1 25 | — | -25.2% | ||
| Q4 24 | — | -5.3% | ||
| Q3 24 | — | -9.6% | ||
| Q2 24 | — | -12.5% | ||
| Q1 24 | — | -15.6% |
净利率MACOFIX
| Q4 25 | -7.2% | -1.0% | ||
| Q3 25 | -34.5% | -11.1% | ||
| Q2 25 | -16.4% | -6.9% | ||
| Q1 25 | -20.1% | -27.4% | ||
| Q4 24 | -77.2% | -13.5% | ||
| Q3 24 | -49.1% | -13.9% | ||
| Q2 24 | 116.9% | -16.8% | ||
| Q1 24 | -60.7% | -19.1% |
每股收益（稀释后）MACOFIX
| Q4 25 | $-0.08 | $-0.05 | ||
| Q3 25 | $-0.34 | $-0.57 | ||
| Q2 25 | $-0.16 | $-0.36 | ||
| Q1 25 | $-0.20 | $-1.35 | ||
| Q4 24 | $-0.95 | $-0.76 | ||
| Q3 24 | $-0.50 | $-0.71 | ||
| Q2 24 | $1.16 | $-0.88 | ||
| Q1 24 | $-0.59 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $280.2M | $82.0M |
| 总债务越低越好 | $5.1B | — |
| 股东权益账面价值 | $2.4B | $450.0M |
| 总资产 | $8.4B | $850.6M |
| 负债/权益比越低杠杆越低 | 2.07× | — |
8季度趋势，按日历期对齐
现金及短期投资MACOFIX
| Q4 25 | $280.2M | $82.0M | ||
| Q3 25 | $290.2M | $62.9M | ||
| Q2 25 | $131.1M | $65.6M | ||
| Q1 25 | $253.2M | $58.0M | ||
| Q4 24 | $89.9M | $83.2M | ||
| Q3 24 | $116.5M | $30.1M | ||
| Q2 24 | $70.7M | $26.4M | ||
| Q1 24 | $120.1M | $27.0M |
总债务MACOFIX
| Q4 25 | $5.1B | — | ||
| Q3 25 | $5.1B | $157.2M | ||
| Q2 25 | $5.2B | $157.0M | ||
| Q1 25 | $5.2B | $156.9M | ||
| Q4 24 | $4.9B | $157.0M | ||
| Q3 24 | $4.3B | $118.5M | ||
| Q2 24 | $4.4B | $118.0M | ||
| Q1 24 | $4.1B | $118.2M |
股东权益MACOFIX
| Q4 25 | $2.4B | $450.0M | ||
| Q3 25 | $2.5B | $442.5M | ||
| Q2 25 | $2.6B | $458.3M | ||
| Q1 25 | $2.7B | $458.3M | ||
| Q4 24 | $2.8B | $503.1M | ||
| Q3 24 | $2.5B | $525.9M | ||
| Q2 24 | $2.5B | $546.0M | ||
| Q1 24 | $2.3B | $570.3M |
总资产MACOFIX
| Q4 25 | $8.4B | $850.6M | ||
| Q3 25 | $8.4B | $832.6M | ||
| Q2 25 | $8.7B | $837.2M | ||
| Q1 25 | $8.7B | $823.1M | ||
| Q4 24 | $8.6B | $893.3M | ||
| Q3 24 | $7.6B | $867.9M | ||
| Q2 24 | $7.8B | $882.0M | ||
| Q1 24 | $7.4B | $906.0M |
负债/权益比MACOFIX
| Q4 25 | 2.07× | — | ||
| Q3 25 | 2.02× | 0.36× | ||
| Q2 25 | 2.02× | 0.34× | ||
| Q1 25 | 1.96× | 0.34× | ||
| Q4 24 | 1.78× | 0.31× | ||
| Q3 24 | 1.73× | 0.23× | ||
| Q2 24 | 1.75× | 0.22× | ||
| Q1 24 | 1.79× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $50.2M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | — | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流MACOFIX
| Q4 25 | $50.2M | $27.7M | ||
| Q3 25 | $112.4M | $12.4M | ||
| Q2 25 | $70.5M | $11.6M | ||
| Q1 25 | $88.5M | $-18.4M | ||
| Q4 24 | $54.9M | $23.7M | ||
| Q3 24 | $100.0M | $11.7M | ||
| Q2 24 | $67.4M | $9.0M | ||
| Q1 24 | $61.1M | $-18.6M |
自由现金流MACOFIX
| Q4 25 | — | $16.8M | ||
| Q3 25 | — | $2.5M | ||
| Q2 25 | — | $4.5M | ||
| Q1 25 | — | $-25.1M | ||
| Q4 24 | — | $15.2M | ||
| Q3 24 | — | $6.3M | ||
| Q2 24 | — | $-360.0K | ||
| Q1 24 | — | $-29.1M |
自由现金流率MACOFIX
| Q4 25 | — | 7.6% | ||
| Q3 25 | — | 1.2% | ||
| Q2 25 | — | 2.2% | ||
| Q1 25 | — | -13.0% | ||
| Q4 24 | — | 7.0% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | — | -0.2% | ||
| Q1 24 | — | -15.4% |
资本支出强度MACOFIX
| Q4 25 | — | 4.9% | ||
| Q3 25 | — | 4.8% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | — | 3.5% | ||
| Q4 24 | — | 4.0% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 4.7% | ||
| Q1 24 | — | 5.6% |
现金转化率MACOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.27× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MAC
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
